Flupentixol/melitracen for epigastric pain syndrome in female patients with abnormal urinalysis and therapeutic insights into the brain–bladder axis
Abstract The pathogenesis of abnormal urinalysis in female epigastric pain syndrome (EPS) is unclear. This study aimed to observe the effect of flupentixol/melitracen (FM) acting in central nervous system on urinalysis in female EPS. It is confirmed that abnormal urinalysis indicators may be related...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-10749-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849763375084470272 |
|---|---|
| author | Fenxia Pu Yixin Li Yurong Liao Xi Wang Guizhen Yong Guobin He |
| author_facet | Fenxia Pu Yixin Li Yurong Liao Xi Wang Guizhen Yong Guobin He |
| author_sort | Fenxia Pu |
| collection | DOAJ |
| description | Abstract The pathogenesis of abnormal urinalysis in female epigastric pain syndrome (EPS) is unclear. This study aimed to observe the effect of flupentixol/melitracen (FM) acting in central nervous system on urinalysis in female EPS. It is confirmed that abnormal urinalysis indicators may be related to somatization caused by abnormal brain-bladder axis. A total of 125 female patients with EPS were randomly assigned to the test and control groups. Patients in the control group (n = 62) received omeprazole for 4 weeks. On this basis, cases in the test group (n = 63) received FM. The changes of dyspepsia symptoms, somatization symptoms and urinalysis were observed at 0 and 4 weeks. In this clinical trial, the score of DSS, somatization symptoms and urinary inflammatory indicators could improve after received FM in female EPS patients with abnormal urinalysis indicators. These results suggest that the brain-bladder axis might contribute to the pathogenesis of EPS, combined with effective anti-somatization or anti-depression treatment is necessary in some female EPS patients with abnormal urinalysis. Further studies are needed to confirm about brain-gut-bladder axis in EPS pathogenesis. Clinical Trials.gov (number: ChiCTR2400079677). |
| format | Article |
| id | doaj-art-fb8ea024f65b47eb893d935b65461b7a |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-fb8ea024f65b47eb893d935b65461b7a2025-08-20T03:05:25ZengNature PortfolioScientific Reports2045-23222025-07-0115111110.1038/s41598-025-10749-wFlupentixol/melitracen for epigastric pain syndrome in female patients with abnormal urinalysis and therapeutic insights into the brain–bladder axisFenxia Pu0Yixin Li1Yurong Liao2Xi Wang3Guizhen Yong4Guobin He5Affiliated Hospital of North Sichuan Medical CollegeAffiliated Hospital of North Sichuan Medical CollegeAffiliated Hospital of North Sichuan Medical CollegeAffiliated Hospital of North Sichuan Medical CollegeAffiliated Hospital of North Sichuan Medical CollegeAffiliated Hospital of North Sichuan Medical CollegeAbstract The pathogenesis of abnormal urinalysis in female epigastric pain syndrome (EPS) is unclear. This study aimed to observe the effect of flupentixol/melitracen (FM) acting in central nervous system on urinalysis in female EPS. It is confirmed that abnormal urinalysis indicators may be related to somatization caused by abnormal brain-bladder axis. A total of 125 female patients with EPS were randomly assigned to the test and control groups. Patients in the control group (n = 62) received omeprazole for 4 weeks. On this basis, cases in the test group (n = 63) received FM. The changes of dyspepsia symptoms, somatization symptoms and urinalysis were observed at 0 and 4 weeks. In this clinical trial, the score of DSS, somatization symptoms and urinary inflammatory indicators could improve after received FM in female EPS patients with abnormal urinalysis indicators. These results suggest that the brain-bladder axis might contribute to the pathogenesis of EPS, combined with effective anti-somatization or anti-depression treatment is necessary in some female EPS patients with abnormal urinalysis. Further studies are needed to confirm about brain-gut-bladder axis in EPS pathogenesis. Clinical Trials.gov (number: ChiCTR2400079677).https://doi.org/10.1038/s41598-025-10749-wEpigastric pain syndromeFlupentixol/melitracenThe somatization symptomsUrinalysis |
| spellingShingle | Fenxia Pu Yixin Li Yurong Liao Xi Wang Guizhen Yong Guobin He Flupentixol/melitracen for epigastric pain syndrome in female patients with abnormal urinalysis and therapeutic insights into the brain–bladder axis Scientific Reports Epigastric pain syndrome Flupentixol/melitracen The somatization symptoms Urinalysis |
| title | Flupentixol/melitracen for epigastric pain syndrome in female patients with abnormal urinalysis and therapeutic insights into the brain–bladder axis |
| title_full | Flupentixol/melitracen for epigastric pain syndrome in female patients with abnormal urinalysis and therapeutic insights into the brain–bladder axis |
| title_fullStr | Flupentixol/melitracen for epigastric pain syndrome in female patients with abnormal urinalysis and therapeutic insights into the brain–bladder axis |
| title_full_unstemmed | Flupentixol/melitracen for epigastric pain syndrome in female patients with abnormal urinalysis and therapeutic insights into the brain–bladder axis |
| title_short | Flupentixol/melitracen for epigastric pain syndrome in female patients with abnormal urinalysis and therapeutic insights into the brain–bladder axis |
| title_sort | flupentixol melitracen for epigastric pain syndrome in female patients with abnormal urinalysis and therapeutic insights into the brain bladder axis |
| topic | Epigastric pain syndrome Flupentixol/melitracen The somatization symptoms Urinalysis |
| url | https://doi.org/10.1038/s41598-025-10749-w |
| work_keys_str_mv | AT fenxiapu flupentixolmelitracenforepigastricpainsyndromeinfemalepatientswithabnormalurinalysisandtherapeuticinsightsintothebrainbladderaxis AT yixinli flupentixolmelitracenforepigastricpainsyndromeinfemalepatientswithabnormalurinalysisandtherapeuticinsightsintothebrainbladderaxis AT yurongliao flupentixolmelitracenforepigastricpainsyndromeinfemalepatientswithabnormalurinalysisandtherapeuticinsightsintothebrainbladderaxis AT xiwang flupentixolmelitracenforepigastricpainsyndromeinfemalepatientswithabnormalurinalysisandtherapeuticinsightsintothebrainbladderaxis AT guizhenyong flupentixolmelitracenforepigastricpainsyndromeinfemalepatientswithabnormalurinalysisandtherapeuticinsightsintothebrainbladderaxis AT guobinhe flupentixolmelitracenforepigastricpainsyndromeinfemalepatientswithabnormalurinalysisandtherapeuticinsightsintothebrainbladderaxis |